-
1.发明授权公开(公告)号：US11241428B2
公开(公告)日：2022-02-08
申请号：US16629457
申请日：2018-07-09
申请人： Medibiofarma, S.L.
IPC分类号： A61K31/496 , A61K45/06 , A61K31/506 , A61K31/444 , C07D401/14 , C07D401/12 , C07D409/14
摘要： The present invention relates to novel heteroaryl amide derivatives of formula (1) as selective inhibitors of histone deacetylase 1 and 2 (hdac1-2) to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said compounds for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by inhibition the activity of histone deacetylase class I, particularly HDAC1 and HDAC2, such as cancer, neurodegenerative diseases, Infectious diseases, inflammatory diseases, heart failure and cardiac hypertrophy, diabetes, polycystic kidney disease, sickle cell disease and β-thalassemia disease and to methods for the treatment of the diseases mentioned above.
-
公开(公告)号：US11267808B2
公开(公告)日：2022-03-08
申请号：US16771514
申请日：2018-12-11
申请人： MEDIBIOFARMA, S.L.
IPC分类号： A61K45/06 , C07D413/04 , C07D213/75 , C07D237/20 , C07D401/04
摘要： The present invention relates to novel benzamides derivatives of formula (I) as modulators of PPAR-gamma receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use in the treatment of pathological conditions, disorders or diseases that can improve by modulation of PPAR-gamma receptor, such as cancer; metabolic diseases, inflammatory diseases, respiratory disorders, autoimmune diseases, neurodegenerative diseases, cardiovascular diseases and renal diseases.
-
公开(公告)号：US11872226B2
公开(公告)日：2024-01-16
申请号：US17310512
申请日：2020-02-07
申请人： MEDIBIOFARMA, S.L.
发明人： Julio Castro Palomino Laria , Juan Camacho Gómez , Rodolfo Rodríguez Iglesias , Irene Velilla Martínez
IPC分类号： A61K31/505 , A61K31/195 , A61K31/277 , A61K31/341 , A61K31/381 , A61K31/415 , A61K31/4418 , C07C233/76 , C07C255/59 , C07D213/56 , C07D231/12 , C07D239/26 , C07D307/58 , C07D333/24
CPC分类号： A61K31/505 , A61K31/195 , A61K31/277 , A61K31/341 , A61K31/381 , A61K31/415 , A61K31/4418 , C07C233/76 , C07C255/59 , C07D213/56 , C07D231/12 , C07D239/26 , C07D307/58 , C07D333/24
摘要： The present invention relates to novel, optionally substituted, N-benzyl-2-phenoxybenzamide derivatives of formula (I), as modulators of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2), to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use in the treatment of pathological conditions, disorders or diseases that can improve by modulation of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2) such as cancer disease, pain, inflammation, neurodegenerative diseases and kidney diseases.
-
4.发明申请公开(公告)号：US20220117962A1
公开(公告)日：2022-04-21
申请号：US17310512
申请日：2020-02-07
申请人： MEDIBIOFARMA, S.L.
发明人： Julio Castro Palomino Laria , Juan Camacho Gómez , Rodolfo Rodríguez Iglesias , Irene Velilla Martínez
IPC分类号： A61K31/505 , C07D213/56 , C07C233/76 , C07D239/26 , C07D333/24 , C07D231/12 , C07D307/58 , C07C255/59 , A61K31/4418 , A61K31/195 , A61K31/381 , A61K31/415 , A61K31/341 , A61K31/277
摘要： The present invention relates to novel, optionally substituted, N-benzyl-2-phenoxybenzamide derivatives of formula (I), as modulators of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2), to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use in the treatment of pathological conditions, disorders or diseases that can improve by modulation of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2) such as cancer disease, pain, inflammation, neurodegenerative diseases and kidney diseases.
-
-
-
搜索结果
4 条记录 (耗时 0.015 秒)
